Molecule for Fragile X Syndrome treatment receives orphan designation
The European Medicines Agency (EMA) has granted "orphan designation" to BMS 204352, a molecule developed by the CNRS to treat Fragile X Syndrome, a rare genetic disease for which there exists no treatment. Protocol assistance ...
Nov 17, 2014
0
0